Pharming Group (NASDAQ:PHAR) Short Interest Down 68.4% in January

Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,500 shares, a decrease of 68.4% from the January 15th total of 23,700 shares. Based on an average daily volume of 7,200 shares, the short-interest ratio is presently 1.0 days.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

Pharming Group Stock Performance

PHAR stock traded up $0.28 during midday trading on Friday, reaching $9.13. The stock had a trading volume of 3,591 shares, compared to its average volume of 5,115. The stock has a market cap of $621.18 million, a PE ratio of -35.12 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The firm has a fifty day simple moving average of $9.33 and a two-hundred day simple moving average of $8.45. Pharming Group has a 52-week low of $6.65 and a 52-week high of $12.20.

Analyst Ratings Changes

Several analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a report on Tuesday, December 17th. Jefferies Financial Group assumed coverage on Pharming Group in a report on Monday, December 9th. They set a "buy" rating and a $14.00 price objective for the company. Finally, Oppenheimer decreased their price objective on Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, October 28th.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.